Biotech News

MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress

MacroGenics (MGNX)MacroGenicsEarnings

Completed MGC028 Phase 1 dose escalation; selected lead indication for dose optimization across two dose levels Reported interim results at ESMO in both Phase 1 study of MGC026 in heavily pretreated SCCHN patients and Phase 2 study of lorigerlimab in CCGC patients First patient dosed with MGC030 in

Related news

MacroGenics

Antibody Engineering Company MacroGenics develops antibody-based cancer therapies using internal platforms for monoclonal antibodies, bispecific molecules, and antibody-drug conjugates. ADC Portfolio MGC026 targets B7-H3 and is in Phase 1 dose expansion, while MGC028 targets ADAM9 and is in Phase 1 dose escalation across advanced solid...

Recent company news

Stock data

Close
1.98 USD
Market cap
257.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States